Confo Therapeutics employs its proprietary CONFO® technology to lock inherently unstable functional conformations of GPCRs as a superior starting point for drug discovery. Confobody-stabilized active state conformations of these receptors reveal previously inaccessible structural features empowering the discovery of novel pathway-selective agonists for improved therapeutic intervention.
